At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 217 enrolled
Drug / intervention
REGN5713 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two-Part Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of the Anti-Bet v 1 Monoclonal Antibodies to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen
In Brief
A Phase 2 clinical trial evaluating REGN5713, REGN5714, and 2 other interventions for Allergic Rhinitis and Conjunctivitis. Completed, enrolled 217 participants across 3 sites.
Detailed Summary
Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU) challenge in participants receiving REGN5713-5714-5715 versus placebo (Part A)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis, Conjunctivitis
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartAug 2022
Primary CompletionJul 2023
TodayJul 2026
First PostedJun 24, 2022
Enrollment StartAug 15, 2022
Primary CompletionJul 31, 2023
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.0 years ago
Interventions
REGN5713drug
Administered subcutaneously (SC)
REGN5714drug
Administered SC
REGN5715drug
Administered SC
Placeboother
Administered SC